Table 2 |
|||
|
Dataset sample numbers for cancer methylation data. |
|||
|
Tissue Type |
Number of Cancer Samples |
Number of Normal Samples |
Technology |
|
|
|||
|
Fackler Breast Tumors |
103 |
21 |
Infinium 27k |
|
Fang Breast Tumors |
39 |
2 |
Infinium 27k |
|
Sproul Breast Tumors |
34 |
2 |
Infinium 27k |
|
Van der Auwera Breast Tumors |
62 |
10 |
Infinium 27k |
|
Colorectal Tumors |
125 |
29 |
Infinium 27k |
|
Illingworth Col. Tum. |
5 |
5 |
MDB-seq |
|
Xu Col. Tum. |
6 |
3 |
MDB-seq |
|
Berman Col. Tum. |
1 |
1 |
WG bis-seq |
|
Prostate Tumors |
95 |
86 |
Infinium 27k |
|
Glioblastomas |
88 |
2 |
Infinium 27k |
|
Lung Tumors |
66 |
24 |
Infinium 27k |
|
AMLs |
188 |
8 |
Infinium 27k |
|
Ovarian Tumors |
484 |
8 |
Infinium 27k |
|
|
|||
|
Details of the number of methylation profiles analyzed for each cancer type. The cancer type, the number of cancer and normal samples analyzed and the technology used to generate the methylation profiles in each case are shown. AMLs, acute myeloid leukemias; Col. Tum, colorectal tumors; Infinium 27k, Illumina infinium Infinium HumanMethylation27 BeadChip array; MBD-seq, Methyl Binding Domain pull-down followed by sequencing; WG bis-seq, whole genome bisulfite sequencing. |
|||
|
Sproul et al. Genome Biology 2012 13:R84 doi:10.1186/gb-2012-13-10-r84 |
|||